Agency Information Collection Activities; Proposed eCollection, eComments Requested; Revision of a Currently Approved Collection; The National Forensic Laboratory Information System Collection of Analysis Data, 63067-63068 [2021-24780]
Download as PDF
Federal Register / Vol. 86, No. 217 / Monday, November 15, 2021 / Notices
63067
Final adjusted
2021
quotas
Basic class
(g)
L-methamphetamine ............................................................................................................................................................................
Meperidine ...........................................................................................................................................................................................
Meperidine Intermediate-A ..................................................................................................................................................................
Meperidine Intermediate-B ..................................................................................................................................................................
Meperidine Intermediate-C ..................................................................................................................................................................
Metazocine ...........................................................................................................................................................................................
Methadone (for sale) ...........................................................................................................................................................................
Methadone Intermediate ......................................................................................................................................................................
Methamphetamine ...............................................................................................................................................................................
D-methamphetamine (for conversion) .................................................................................................................................................
D-methamphetamine (for sale) ............................................................................................................................................................
Methylphenidate (for conversion) ........................................................................................................................................................
Methylphenidate (for sale) ...................................................................................................................................................................
Metopon ...............................................................................................................................................................................................
Moramide-intermediate ........................................................................................................................................................................
Morphine (for conversion) ....................................................................................................................................................................
Morphine (for sale) ..............................................................................................................................................................................
Nabilone ...............................................................................................................................................................................................
Norfentanyl ...........................................................................................................................................................................................
Noroxymorphone (for conversion) .......................................................................................................................................................
Noroxymorphone (for sale) ..................................................................................................................................................................
Oliceridine ............................................................................................................................................................................................
Opium (powder) ...................................................................................................................................................................................
Opium (tincture) ...................................................................................................................................................................................
Oripavine ..............................................................................................................................................................................................
Oxycodone (for conversion) ................................................................................................................................................................
Oxycodone (for sale) ...........................................................................................................................................................................
Oxymorphone (for conversion) ............................................................................................................................................................
Oxymorphone (for sale) .......................................................................................................................................................................
Pentobarbital ........................................................................................................................................................................................
Phenazocine ........................................................................................................................................................................................
Phencyclidine .......................................................................................................................................................................................
Phenmetrazine .....................................................................................................................................................................................
Phenylacetone .....................................................................................................................................................................................
Piminodine ...........................................................................................................................................................................................
Racemethorphan .................................................................................................................................................................................
Racemorphan ......................................................................................................................................................................................
Remifentanil .........................................................................................................................................................................................
Secobarbital .........................................................................................................................................................................................
Sufentanil .............................................................................................................................................................................................
Tapentadol ...........................................................................................................................................................................................
Thebaine ..............................................................................................................................................................................................
587,229
856,695
30
30
30
15
25,619,700
27,673,600
50
485,020
40,000
15,300,000
57,438,334
25
25
3,376,696
26,505,995
62,000
25
22,044,741
376,000
22,500
250,000
530,837
33,010,750
620,887
57,110,032
28,204,371
563,174
30,766,670
25
35
25
6,100,000
25
5
5
3,000
172,100
4,000
13,447,541
57,137,944
List I Chemicals
Ephedrine (for conversion) ..................................................................................................................................................................
Ephedrine (for sale) .............................................................................................................................................................................
Phenylpropanolamine (for conversion) ................................................................................................................................................
Phenylpropanolamine (for sale) ...........................................................................................................................................................
Pseudoephedrine (for conversion) ......................................................................................................................................................
Pseudoephedrine (for sale) .................................................................................................................................................................
khammond on DSKJM1Z7X2PROD with NOTICES
The Administrator further proposes
that APQ for all other schedule I and II
controlled substances included in 21
CFR 1308.11 and 1308.12 remain at
zero.
Anne Milgram,
Administrator.
[FR Doc. 2021–24921 Filed 11–10–21; 4:15 pm]
BILLING CODE 4410–09–P
[OMB Number 1117–0034]
Agency Information Collection
Activities; Proposed eCollection,
eComments Requested; Revision of a
Currently Approved Collection; The
National Forensic Laboratory
Information System Collection of
Analysis Data
Drug Enforcement
Administration, Department of Justice.
ACTION: 30-Day Notice.
AGENCY:
VerDate Sep<11>2014
16:42 Nov 12, 2021
Jkt 256001
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
The Department of Justice
(DOJ), Drug Enforcement
Administration (DEA), will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
This proposed information collection
was previously published in the Federal
Register at 86 FR 47523 on August 25,
2021, allowing for a 60 day comment
period. No comments were received.
SUMMARY:
DEPARTMENT OF JUSTICE
100
4,136,000
14,878,320
16,690,000
1,000
174,246,000
E:\FR\FM\15NON1.SGM
15NON1
63068
Federal Register / Vol. 86, No. 217 / Monday, November 15, 2021 / Notices
Comments are encouraged and
will be accepted for an additional 30
days until December 15, 2021.
FOR FURTHER INFORMATION CONTACT:
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
SUPPLEMENTARY INFORMATION:
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address one or more
of the following four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information proposed to be collected
can be enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other forms of
information technology, e.g.,
permitting electronic submission of
responses.
DATES:
khammond on DSKJM1Z7X2PROD with NOTICES
Overview of This Information
Collection
1. Type of Information Collection:
Revision of a currently approved
collection.
2. Title of the Form/Collection: The
National Forensic Laboratory
Information System Collection of
Analysis Data.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
There are no form numbers associated
with this collection. The applicable
component within the Department of
Justice is the Drug Enforcement
Administration, Diversion Control
Division.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract:
Affected public (Primary): Forensic
Science Laboratory Management.
VerDate Sep<11>2014
16:42 Nov 12, 2021
Jkt 256001
Affected public (Other): None.
Abstract: This collection provides the
Drug Enforcement Administration
(DEA) with a national database on
analyzed drug evidence from nonfederal laboratories. Information from
this database is combined with the other
existing databases to develop more
accurate, up-to-date information on
abused drugs. This database represents
a voluntary, cooperative effort on the
part of participating laboratories to
provide a centralized source of analyzed
drug data.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: DEA estimates that 2,640
persons annually for this collection at
2.2015 hour per respondent, for an
annual burden of 5,812 hours.
6. An estimate of the total public
burden (in hours) associated with the
proposed collection: DEA estimates that
this collection takes 5,812 annual
burden hours.
If additional information is required
please contact: Melody Braswell,
Department Clearance Officer, United
States Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, Suite 3E.405B,
Washington, DC 20530.
Dated: November 8, 2021.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2021–24780 Filed 11–12–21; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
Federal-State Unemployment
Compensation Program: Certifications
for 2021 Under the Federal
Unemployment Tax Act
Employment and Training
Administration, Department of Labor.
ACTION: Notice.
AGENCY:
The Secretary of Labor signed
the annual certifications under the
Federal Unemployment Tax Act, 26
U.S.C. 3301 et seq., thereby enabling
employers who make contributions to
state unemployment funds to obtain
certain credits against their liability for
the federal unemployment tax. By letter,
the certifications were transmitted to the
Secretary of the Treasury. The letter and
certifications are printed below.
SUMMARY:
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
Signed in Washington, DC, October 31,
2021.
Angela Hanks,
Acting Assistant Secretary, Employment and
Training.
The Honorable Janet L. Yellen
Secretary of the Treasury
Department of the Treasury
1500 Pennsylvania Avenue NW
Washington, DC 20220
Dear Secretary Yellen:
Enclosed are an original and a copy of
each of two separate certifications
regarding state unemployment
compensation laws pursuant to the
Federal Unemployment Tax Act, for the
12-month period ending on October 31,
2021. One certification is with respect to
the ‘‘normal’’ federal unemployment tax
credit under Section 3304 of the Internal
Revenue Code of 1986 (IRC), and the
other certification is with respect to the
‘‘additional’’ tax credit under Section
3303 of the IRC. Both certifications list
all 53 states.
Sincerely,
MARTIN J. WALSH
CERTIFICATION OF STATES TO THE
SECRETARY OF THE TREASURY
PURSUANT TO SECTION 3304(c) OF
THE INTERNAL REVENUE CODE OF
1986
In accordance with the provisions of
Section 3304(c) of the Internal Revenue
Code of 1986 (26 U.S.C. 3304(c)), I
hereby certify the following named
states to the Secretary of the Treasury
for the 12-month period ending on
October 31, 2021, in regard to the
unemployment compensation laws of
those states, which heretofore have been
approved under the Federal
Unemployment Tax Act:
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
E:\FR\FM\15NON1.SGM
15NON1
Agencies
[Federal Register Volume 86, Number 217 (Monday, November 15, 2021)]
[Notices]
[Pages 63067-63068]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-24780]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
[OMB Number 1117-0034]
Agency Information Collection Activities; Proposed eCollection,
eComments Requested; Revision of a Currently Approved Collection; The
National Forensic Laboratory Information System Collection of Analysis
Data
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: 30-Day Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Justice (DOJ), Drug Enforcement
Administration (DEA), will be submitting the following information
collection request to the Office of Management and Budget (OMB) for
review and approval in accordance with the Paperwork Reduction Act of
1995. This proposed information collection was previously published in
the Federal Register at 86 FR 47523 on August 25, 2021, allowing for a
60 day comment period. No comments were received.
[[Page 63068]]
DATES: Comments are encouraged and will be accepted for an additional
30 days until December 15, 2021.
FOR FURTHER INFORMATION CONTACT: Written comments and recommendations
for the proposed information collection should be sent within 30 days
of publication of this notice to www.reginfo.gov/public/do/PRAMain.
Find this particular information collection by selecting ``Currently
under 30-day Review--Open for Public Comments'' or by using the search
function.
SUPPLEMENTARY INFORMATION:
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address one or more of the following
four points:
--Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility;
--Evaluate the accuracy of the agency's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used;
--Evaluate whether and if so how the quality, utility, and clarity of
the information proposed to be collected can be enhanced; and
--Minimize the burden of the collection of information on those who are
to respond, including through the use of appropriate automated,
electronic, mechanical, or other forms of information technology, e.g.,
permitting electronic submission of responses.
Overview of This Information Collection
1. Type of Information Collection: Revision of a currently approved
collection.
2. Title of the Form/Collection: The National Forensic Laboratory
Information System Collection of Analysis Data.
3. The agency form number, if any, and the applicable component of
the Department sponsoring the collection: There are no form numbers
associated with this collection. The applicable component within the
Department of Justice is the Drug Enforcement Administration, Diversion
Control Division.
4. Affected public who will be asked or required to respond, as
well as a brief abstract:
Affected public (Primary): Forensic Science Laboratory Management.
Affected public (Other): None.
Abstract: This collection provides the Drug Enforcement
Administration (DEA) with a national database on analyzed drug evidence
from non-federal laboratories. Information from this database is
combined with the other existing databases to develop more accurate,
up-to-date information on abused drugs. This database represents a
voluntary, cooperative effort on the part of participating laboratories
to provide a centralized source of analyzed drug data.
5. An estimate of the total number of respondents and the amount of
time estimated for an average respondent to respond: DEA estimates that
2,640 persons annually for this collection at 2.2015 hour per
respondent, for an annual burden of 5,812 hours.
6. An estimate of the total public burden (in hours) associated
with the proposed collection: DEA estimates that this collection takes
5,812 annual burden hours.
If additional information is required please contact: Melody
Braswell, Department Clearance Officer, United States Department of
Justice, Justice Management Division, Policy and Planning Staff, Two
Constitution Square, 145 N Street NE, Suite 3E.405B, Washington, DC
20530.
Dated: November 8, 2021.
Melody Braswell,
Department Clearance Officer for PRA, U.S. Department of Justice.
[FR Doc. 2021-24780 Filed 11-12-21; 8:45 am]
BILLING CODE 4410-09-P